Compositions and methods for treating cancer
Modified Stella peptides and nucleic acid molecules are used to modulate UHRF1 protein activity, addressing the challenge of treating colorectal cancer by inhibiting abnormal DNA methylation maintenance and reactivating tumor suppressor genes.
Patent Information
- Application Number
- PCT/US2024/047764
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-09-20
- Filing Date
- 2024-09-20
- Publication Date
- 2025-03-27
AI Technical Summary
Current treatments for cancer, particularly colorectal cancer, are limited in effectively targeting and modulating the UHRF1 protein, which plays a crucial role in maintaining abnormal DNA methylation patterns associated with cancer.
The development of compositions comprising modified peptides, specifically mutated or synthetic Stella peptides and nucleic acid molecules encoding these peptides, which can modulate the expression or activity of the UHRF1 protein. These peptides exhibit substantial sequence identity to native Stella proteins and can inhibit UHRF1's binding to DNA methylation sites, histones, and chromatin.
The proposed solution effectively inhibits UHRF1's maintenance of abnormal DNA methylation, leading to potential therapeutic benefits in treating various cancers, including colorectal cancer, by reactivating epigenetically silenced tumor suppressor genes.